Aerobic exercise is a vital treatment for people living with Parkinson’s disease. Although anti-parkinsonian medication helps alleviate Parkinson’s symptoms, it is not known to slow the rate of disease progression. Aerobic exercise is a treatment with the most compelling evidence for its potential to slow Parkinson's disease progression. While both moderate- and high-intensity aerobic exercise provides health benefits, it is currently unclear which intensity is more effective for people with Parkinson’s.
The SPARX3 (NCT04284436) study is the first randomized control trial designed to investigate the effects of moderate- and high-intensity aerobic exercise on disease progression in untreated patients with Parkinson’s.
Research reported in this film-clip was supported by the National Institute Of Neurological Disorders And Stroke of the National Institutes of Health under Award Number U01NS113851. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Are you interested in becoming part of the SPARX3 research study?
We are actively recruiting participants. Learn more about how you can become a participant here.